Department of Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China.
Hepatobiliary Pancreat Dis Int. 2013 Jun;12(3):295-304. doi: 10.1016/s1499-3872(13)60047-8.
The increased beta-arrestin-2 and its combination with G-protein-coupled receptors (GPCRs) lead to GPCRs desensitization. The latter may be responsible for decreased contractile reactivity in the mesenteric arteries of cirrhotic patients and rats. The present study is to investigate the machinery changes of alpha-adrenergic receptors and G proteins and their roles in the contractility of mesenteric arteries of cirrhotic patients and animal models.
Patients with cirrhosis due to hepatitis B and cirrhotic rats induced by CCl4 were studied. Mesenteric artery contractility in response to norepinephrine was determined by a vessel perfusion system. The contractile effect of G protein-coupled receptor kinase-2 (GRK-2) inhibitor on the mesenteric artery was evaluated. The protein expression of the alpha1 adrenergic receptor, G proteins, beta-arrestin-2, GRK-2 as well as the activity of Rho associated coiled-coil forming protein kinase-1 (ROCK-1) were measured by Western blot. In addition, the interaction of alpha1 adrenergic receptor with beta-arrestin-2 was assessed by co-immunoprecipitation.
The portal vein pressure of cirrhotic patients and rats was significantly higher than that of controls. The dose-response curve to norepinephrine in mesenteric arteriole was shifted to the right, and EC50 was significantly increased in cirrhotic patients and rats. There were no significant differences in the expressions of the alpha1 adrenergic receptor and G proteins in the cirrhotic group compared with the controls. However, the protein expressions of GRK-2 and beta-arrestin-2 were significantly elevated in cirrhotic patients and rats compared with those of the controls. The interaction of the alpha1 adrenergic receptor and beta-arrestin-2 was significantly aggravated. This interaction was significantly reversed by GRK-2 inhibitor. Both the protein expression and activity of ROCK-1 were significantly decreased in the mesenteric artery in patients with cirrhosis compared with those of the controls, and this phenomenon was not shown in the cirrhotic rats. Norepinephrine significantly increased the activity of ROCK-1 in normal rats but not in cirrhotic ones. Norepinephrine significantly increased ROCK-1 activity in cirrhotic rats when GRK-2 inhibitor was used.
beta-arrestin-2 expression and its interaction with GPCRs are significantly upregulated in the mesenteric arteries in patients and rats with cirrhosis. These upregulations result in GPCR desensitization, G-protein dysfunction and ROCK inhibition. These may explain the decreased contractility of the mesenteric artery in response to vasoconstrictors.
β-arrestin-2 的增加及其与 G 蛋白偶联受体 (GPCRs) 的结合导致 GPCR 脱敏。后者可能是导致肝硬化患者和大鼠肠系膜动脉收缩反应性降低的原因。本研究旨在探讨α-肾上腺素能受体和 G 蛋白的机制变化及其在肝硬化患者和动物模型肠系膜动脉收缩中的作用。
研究了乙型肝炎引起的肝硬化患者和四氯化碳诱导的肝硬化大鼠的肠系膜动脉收缩性。通过血管灌注系统测定去甲肾上腺素对肠系膜动脉的收缩反应。评估 G 蛋白偶联受体激酶-2 (GRK-2) 抑制剂对肠系膜动脉的收缩作用。通过 Western blot 测定α1 肾上腺素能受体、G 蛋白、β-arrestin-2、GRK-2 的蛋白表达以及 ROCK-1 的活性。此外,通过共免疫沉淀评估α1 肾上腺素能受体与β-arrestin-2 的相互作用。
肝硬化患者和大鼠的门静脉压明显高于对照组。肠系膜小动脉对去甲肾上腺素的量效曲线右移,EC50 明显升高。肝硬化组与对照组相比,α1 肾上腺素能受体和 G 蛋白的表达无明显差异。然而,与对照组相比,肝硬化患者和大鼠的 GRK-2 和β-arrestin-2 蛋白表达明显升高。α1 肾上腺素能受体与β-arrestin-2 的相互作用明显加重。GRK-2 抑制剂显著逆转了这种相互作用。与对照组相比,肝硬化患者的肠系膜动脉中 ROCK-1 的蛋白表达和活性明显降低,而在肝硬化大鼠中则没有这种现象。去甲肾上腺素显著增加正常大鼠但不增加肝硬化大鼠的 ROCK-1 活性。当使用 GRK-2 抑制剂时,去甲肾上腺素显著增加肝硬化大鼠的 ROCK-1 活性。
肝硬化患者和大鼠的肠系膜动脉中β-arrestin-2 的表达及其与 GPCRs 的相互作用明显上调。这些上调导致 GPCR 脱敏、G 蛋白功能障碍和 ROCK 抑制。这可能解释了血管收缩剂引起的肠系膜动脉收缩性降低。